Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 6, 37817

Effects of Annual Influenza Vaccination on Morbidity and Mortality in Patients With Systemic Lupus Erythematosus: A Nationwide Cohort Study

Affiliations

Effects of Annual Influenza Vaccination on Morbidity and Mortality in Patients With Systemic Lupus Erythematosus: A Nationwide Cohort Study

Chi-Ching Chang et al. Sci Rep.

Abstract

Studies on the clinical efficacy of influenza vaccination on patients with systemic lupus erythematosus (SLE) are scant. The present study compared the incidence of hospitalization, morbidity, and mortality in patients with SLE between cohorts with and without influenza vaccination. We used the Taiwan's insurance claims data between 2001 and 2012 for identifying annual adult patients with SLE with (N = 1765) and without (N = 8360) influenza vaccination. The incidence rate ratio and hazard ratio (HR) for morbidities and mortality were measured for the vaccine and nonvaccine cohorts. The vaccine cohort had a lower hospitalization rate than did the nonvaccine cohort, with an adjusted HR of 0.82 (95% CI 0.73-0.92). Furthermore, the vaccine cohort was less likely to be admitted to the intensive care unit [adjusted HR 0.55 (95% CI 0.39-0.79)], to be hospitalized for septicemia, bacteremia, or viremia [adjusted HR 0.48 (95% CI 0.32-0.73)], to undergo in-hospital dialysis [adjusted HR 0.40 (95% CI 0.20-0.81)], and were less predisposed to death [adjusted HR 0.41 (95% CI 0.27-0.61)]. In conclusion, influenza vaccination in patients with SLE is associated with a reduced risk of morbidity and mortality.

Figures

Figure 1
Figure 1
Estimated baseline cumulative hazard rate for different outcomes under the Cox proportional hazard model in patients with SLE with and without vaccination (a) Total hospitalization (b) Hospitalization for pneumonia (c) Hospitalization for septicemia, bacteremia, or viremia (d) Intensive care unit admission (e) In-hospital dialysis (f) Death.

Similar articles

See all similar articles

Cited by 4 articles

References

    1. Bouza E., Moya G. L. & Munoz P. Infections in systemic lupus erythematosus and rheumatoid arthritis. Infect Dis Clin N Am. 15, 335–361 (2001). - PubMed
    1. Alarcón G. S. Infections in Systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis. Infect Dis Clin N Am. 20, 849–875 (2006). - PubMed
    1. Fessler B. J. Infectious diseases in systemic lupus erythematosus: risk factors, management and prophylaxis. Best Pract Res Clin Rheumatol. 16, 281–291 (2002). - PubMed
    1. Nicholson K. G., Wood J. M. & Zambon M. Influenza. Lancet. 362, 1733–1745 (2003). - PMC - PubMed
    1. Thompson W. W. et al. . Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 289, 179–186 (2003). - PubMed

MeSH terms

Substances

Feedback